Apricus re licenses rights to erectile dysfunction drug Vitaros (alprostadil topical)from Allergan

Apricus Biosciences, Inc. announced that it has licensed the U.S. development and commercialization rights for Vitaros (alprostadil topical) from Allergan. Under the license agreement, Apricus will be responsible for all Vitaros development efforts in the United States. Upon the FDA acceptance of a New Drug Application ("NDA") for Vitaros, Allergan may elect to exercise its one time opt-in right to assume all future marketing and selling activities in the United States in exchange for certain financial considerations.

Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction and a new potential entrant into the U.S. treatment market. On February 3, 2009, Warner Chilcott, now a subsidiary of Allergan, acquired the U.S. rights to Vitaros from Apricus. Since that time, Vitaros has been approved by the European health authorities and by Health Canada, and is currently being promoted by Apricus' licensees throughout Europe. Apricus will pay Allergan a double-digit royalty. Allergan also retained the right to launch an authorized generic of Vitaros under a profit share agreement with Apricus.